Exhaled nitric oxide is related to atopy, but not asthma in adolescents with bronchiolitis in infancy

BMC Pulmonary Medicine

Table 2 Characteristics of 90 children in an age matched control group at 11 years of age, according to asthma and atopy

	Healthy (n = 51)	Atopic non-asthmatic (n = 29)	P-value	Current non-atopic asthma (n = 5)	P-value	Current atopic asthma (n = 5)	P-value
Boys, n (%)	31 (61)	16 (55)	0.644	4 (80)	0.640	4 (80)	0.640
Age at follow up^* (year)	11.8 (11.4, 12.2)	11.4 (11.0, 12.1)	0.081	12.3 (11.4, 12.8)	0.147	11.8 (10.9, 12.0)	0.502
Weight at follow-up^† (kg)	41.7 (8.5)	40.9 (9.4)	0.677	47.9 (17.3)	0.472	51.4 (25.7)	0.449
Height at follow-up^† (cm)	151.9 (7.6)	149.0 (7.0)	0.087	150.8 (10.2)	0.749	152.0 (17.1)	0.998
ICS, n (%)	1 (2)	0	1.000	3 (60)	0.001	4 (80)	<0.001
FEV₁%^†	98.7 (10.6)	99.8 (7.9)	0.631	101.9 (10.7)	0.510	96.3 (28.3)	0.864
FEF_25–75%^†	96.9 (22.9)	98.9 (16.1)	0.693	95.6 (18.9)	0.903	93.3 (45.7)	0.764
FEV₁ /FVC ratio^†	84.3 (6.6)	84.2 (4.5)	0.969	79.8 (4.2)	0.146	80.8 (6.7)	0.269
DRS to methacholine^*	1.7 (1.0, 6.8)	3.6 (0.8,17.6)	0.084	0.9 (0.3, 5.8)	0.292	4.7 (1.1, 24.5)	0.405

^*Median (inter quartile range), ^†mean (standard deviation). ICS, inhaled corticosteroids last 12 months before follow up; FEV₁%, forced expiratory volume in first second as percentage of predicted; FEF_25–75%, forced expiratory flow between 25-75% of the forced vital capacity (FVC) as percentage of predicted; DRS, dose response slope. For missing data, see text. P-values assess comparisons with the healthy group.
Bold values indicate significance at the 0.05 level.

ISSN: 1471-2466